Disease · MONDO_0005477
ventricular tachycardia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. ventricular tachycardia. Diseases, record MONDO_0005477. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005477
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs24
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AMIODARONE | CHEMBL633 | Small molecule | Approval | TTD | 10 | 9 | 9 | Drugs and targets |
| MEXILETINE | CHEMBL558 | Small molecule | Approval | TTD | 4 | 3 | 3 | Drugs and targets |
| AMIODARONE HYDROCHLORIDE | CHEMBL1083993 | Small molecule | Approval | DailyMed and PMDA | 10 | 1 | 1 | Drugs and targets |
| ZIPRASIDONE HYDROCHLORIDE | CHEMBL1375743 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| SOTALOL | CHEMBL471 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| RANOLAZINE | CHEMBL1404 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IMIPRAMINE | CHEMBL11 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROCAINAMIDE | CHEMBL640 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| QUINIDINE | CHEMBL1294 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 24
See all 24 drugsTargets27
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SCN5A | Sodium channel alpha subunit | 6 | Sodium channel alpha subunit blocker; Sodium channel protein type V alpha subunit blocker | Approval | https://conductscience.org/library/genes/6331 | Drugs and targets |
| ADRB1 | Adrenergic receptor beta | 5 | Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 5 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Approval | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6332 | Drugs and targets |
| SCN8A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Approval | https://conductscience.org/library/genes/6334 | Drugs and targets |
1 to 10 of 27
See all 27 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01401647 | Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia | Phase 3 | 3,024 | 2017-01-30 | Cardiac Arrest | AMIODARONE, LIDOCAINE | Its record names the disease | ClinicalTrials.gov |
| NCT01215253 | Ranolazine Implantable Cardioverter-Defibrillator Trial | Phase 3 | 1,012 | 2018-06-15 | Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure | RANOLAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT04134845 | A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias. | Phase 2/3 | 68 | 2025-08-15 | Ventricular Tachycardia | DANTROLENE | Its record names the disease | ClinicalTrials.gov |
| NCT02301390 | INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events | Not applicable | 53 | 2020-01-27 | Ventricular Tachycardia | AMIODARONE | Its record names the disease | ClinicalTrials.gov |
| NCT01576042 | Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator | Not applicable | 27 | 2014-09-25 | Ventricular Tachycardia | AMIODARONE, SOTALOL | Its record names the disease | ClinicalTrials.gov |
| NCT03685149 | Pilot Randomized Trial With Flecainide in ARVC Patients | Phase 2 | 22 | 2024-08-20 | Arrhythmogenic Right Ventricular Cardiomyopathy | FLECAINIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01097330 | Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patients With Ventricular Tachycardia | Phase 3 | 12 | 2020-01-29 | Defibrillators, Implantable, Tachycardia, Ventricular | AMIODARONE | Its record names the disease | ClinicalTrials.gov |
| NCT02360397 | Ranolazine Mediated PVC Reduction in Ischemic Heart Disease | Phase 2 | 6 | 2020-01-29 | Ventricular Premature Complexes, Myocardial Ischemia | RANOLAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT03853369 | Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection | 2,000 | Ventricular Tachycardia, Ventricular Fibrillation | NIFEKALANT | Its record names the disease | ClinicalTrials.gov | ||
| NCT06680869 | Early Amiodarone in Shockable Cardiac Arrest | Phase 3 | 585 | Cardiac Arrest | AMIODARONE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials30
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ranolazine vs Placebo: Number of Patients With Heart Failure Hospitalization or Death, Whichever Occurred First | 144 of 510 | 140 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients Whose First VT/VF Required Antitachycardia Pacing (ATP) | 92 of 510 | 117 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients With Hospitalization for Cardiac Causes or Death, Whichever Occurred First. | 237 of 510 | 222 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients With VT or VF Requiring ICD Shock or Death | 131 of 510 | 145 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Death | 70 of 510 | 78 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients Whose First VT/VF Required ICD Shock | 79 of 510 | 84 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients With Ventricular Tachycardia (VT) or Ventricular Fibrillation (VF) or Death | 174 of 510 | 198 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: deaths from any cause | 70 of 510 | 78 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: Number of Patients With First Inappropriate ICD Shock | 16 of 510 | 20 of 502 | 1,012 | NCT01215253 | Trial comparisons |
| Ranolazine vs Placebo: serious adverse events | 0 of 510 | 0 of 502 | 1,012 | NCT01215253 | Trial comparisons |
1 to 10 of 30
See all 30 comparisons in its trialsPapers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005477
GET https://conductscience.org/api/diseases/v1/MONDO_0005477/drugs?page=2